Brought to you by 
Iterum closes $65mm Series B
19 May 2017
Executive Summary
Infectious disease-focused Iterum Therapeutics Ltd. raised $65mm through its Series B financing led by Arix Bioscience, which was joined by other first-time backers Pivotal bioVenture Partners, Advent Life Sciences, Domain Associates, and Bay City Capital along with returning shareholders Frazier Healthcare Partners, Canaan Partners, Sofinnova Ventures, and New Leaf Venture Partners. The company will use some of the funds for Phase III trials (expected in H1 2018) of its sulopenem antibiotic for uncomplicated urinary tract infections and will also put funds towards production of clinical supplies and registration batches. A representative from Arix, Pivotal, and Advent will join the board.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Iterum closes $65mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice